Wasatch Advisors LP Sells 161,888 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Wasatch Advisors LP reduced its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 21.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 607,364 shares of the medical device company's stock after selling 161,888 shares during the period. Wasatch Advisors LP owned approximately 1.25% of AtriCure worth $18,561,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of ATRC. State Street Corp lifted its position in shares of AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock worth $37,710,000 after buying an additional 63,002 shares during the last quarter. Geode Capital Management LLC boosted its position in AtriCure by 2.9% in the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock valued at $32,326,000 after buying an additional 32,676 shares in the last quarter. Silver Oak Securities Incorporated bought a new stake in shares of AtriCure during the fourth quarter worth $220,000. JPMorgan Chase & Co. increased its holdings in shares of AtriCure by 43.1% during the fourth quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock worth $11,160,000 after buying an additional 110,039 shares in the last quarter. Finally, Calamos Advisors LLC lifted its stake in shares of AtriCure by 27.9% in the 4th quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock valued at $3,382,000 after acquiring an additional 24,147 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ATRC. Stifel Nicolaus increased their target price on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Piper Sandler lifted their target price on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Canaccord Genuity Group decreased their price target on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $51.00 target price on shares of AtriCure in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $49.44.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 3.20% of the company's stock.

AtriCure Trading Down 0.3 %

Shares of ATRC stock traded down $0.09 during trading hours on Tuesday, hitting $31.66. 72,323 shares of the company were exchanged, compared to its average volume of 653,434. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The company has a 50 day simple moving average of $34.88 and a two-hundred day simple moving average of $34.49. The firm has a market cap of $1.55 billion, a P/E ratio of -33.36 and a beta of 1.65.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.